HIGHCPSC

Plantimex Recalls Mamisan Ointment Due to Child Poisoning Risk

Plantimex recalled Mamisan Pain Relieving Topical Ointment on December 18, 2025. The ointment's packaging does not comply with child-resistant standards, posing a serious poisoning risk to children. Consumers should stop using the product immediately and secure it out of children's reach.

Official notice
Recalled Mamisan Licodaine Ointment jar UPC - 860006498115
Recalled Mamisan Licodaine Ointment jar UPC - 860006498115
Official source
CPSC
Recall date
December 18, 2025
Status
ACTIVE
Severity
8/10

Quick Facts at a Glance

Recall Date
December 18, 2025
Hazard Level
HIGH
Brands
MiramarLab, of Doral, Florida, Plantimex, Mamisan
Category
Health & Personal Care
Sold At
Multiple Retailers
At-Risk Groups
CHILDREN

What to Do Now

Use this page like a recall checklist: verify the product first, then act on the official remedy.

Immediate steps

  1. 1Stop using the product until you confirm whether it is included in the recall.
  2. 2Compare the product label, model number, UPC, color, size, and purchase location against the identifiers below.
  3. 3Follow the official remedy from Consumer Product Safety Commission; save photos, receipts, labels, and correspondence before contacting the company.
  4. 4If the product could harm a child, older adult, pet, or patient, move it out of reach immediately.

Check these identifiers

Brand
MiramarLab, of Doral, Florida, Plantimex, Mamisan
Product type
Pain Relieving Ointment
UPC codes
860006498115
Colors
orange
Sizes
3.52 ounce
Sold at
Multiple Retailers

Recall Timeline

Key dates and source checks for this recall record.

  1. Recall announced

    December 18, 2025

  2. Reported by CPSC

    December 18, 2025

  3. RecallRadar source check

    December 25, 2025

  4. Consumer action

    Use the official remedy and keep documentation.

More Product Images

Recalled Mamisan Lidocaine Ointment 3.52 ounce jar
Recalled Mamisan Lidocaine Ointment 3.52 ounce jar
Recalled Mamisan Lidocaine Ointment jar non-child resistant packaging (continuous thread lid)
Recalled Mamisan Lidocaine Ointment jar non-child resistant packaging (continuous thread lid)

Hazard Information

The ointment contains lidocaine, which must be in child-resistant packaging, as required by the Poison Prevention Packaging Act. The ointment's packaging is not child-resistant, posing a risk of serious injury or death from poisoning if the contents are swallowed by young children.

What You Should Do

Consumers should stop using the product immediately. Plantimex toll-free at 855-752-6869 from 9 a.m. to 4 p.m. PT Monday through Friday, email at customercare@plantimexusa.com with the subject "RECALL" or online at http://plantimexusa.com/contact.php or www.plantimexusa.com and contact us for more information.. Consumers should immediately secure the recalled ointment jars out of the sight and reach of children and contact Plantimex to receive a free replacement lid. Once the product is secured with the replacement lid, consumers can use the product, as directed.. Available options: Repair

About This Product

Mamisan Pain Relieving Ointment is a topical treatment used to relieve minor pain. It is often purchased for its effectiveness in soothing discomfort in various body parts.

Why This Is Dangerous

The ointment contains lidocaine, which is effective for pain relief but can be dangerous if ingested by children. The lack of child-resistant packaging allows easy access to the ointment by young children, increasing the risk of accidental poisoning.

Industry Context

This recall is not part of a broader industry pattern.

Real-World Impact

The recall affects consumers who use Mamisan Ointment for pain relief, particularly households with children. The potential poisoning risk requires immediate action to secure the product.

Practical Guidance

How to identify if yours is affected

  1. Locate the UPC code on the bottom of the jar.
  2. Check if it matches the recalled UPC 860006498115.
  3. Identify the jar's color and size (orange, 3.52 ounces).

Where to find product info

The UPC code is typically found on the bottom or back of the jar.

What timeline to expect

Expect 4-6 weeks for the refund or replacement process after contacting Plantimex.

If the manufacturer is unresponsive

  • Document all communication attempts with Plantimex.
  • Consider reaching out to consumer protection agencies for further assistance.

How to prevent similar issues

  • Look for child-resistant packaging when purchasing topical ointments.
  • Check for safety certifications on over-the-counter medications.
  • Read product labels carefully for safety warnings.

Documentation advice

Keep records of your purchase, including receipts and correspondence regarding the recall.

Get instant alerts for Health & Personal Care recalls

Be the first to know. Free instant alerts to your inbox.

No spamUnsubscribe anytime

Product Details

This recall involves Mamisan Pain Relieving Topical Ointment sold in 3.52 ounce plastic jars. The jars are orange with a white continuous thread lid, printed with the Mamisan trademark. Only jars with UPC code 860006498115 are included in the recall.

Key Facts

  • Recall date: December 18, 2025
  • Only jars with UPC 860006498115 are affected
  • Potential risk of poisoning to children
  • Contact Plantimex for a replacement lid

Browse More Recalls

Safety Guide

Not sure what to do next? Our guide walks you through the process step by step.

Read: What to Do When You Find a Recalled Product

Get Alerts for Health & Personal Care Recalls

Get instant alerts for recalls that affect you. Free forever.

Safety Assessment

Risk LevelHIGH
Severity Score
8/ 10
Affected Groups
CHILDREN
Injury Types
POISONING

Product Details

UPC Codes
860006498115
Report Date
December 18, 2025
Recall Status
ACTIVE

Related Recalls

Health & Personal Care
MEDIUM

AvKARE Recalls Rosuvastatin Tablets Due to Dissolution Issues

AvKARE recalled 7,991 cartons of Rosuvastatin Tablets on December 31, 2025. The recall stems from the product being out of specification for dissolution. Consumers should stop using the medication immediately and consult healthcare providers for guidance.

SUN PHARMACEUTICAL INDUSTRIES
Labeling: Not
Read more